Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 15/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 14/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165982 | 0.89 | GSK3B (0.47) | WNT1GSK3BDYRK1AROCK1ROCK2 | |
| SCHEMBL562527 | 0.82 | GSK3B (0.46) | WNT1GSK3BDYRK1AROCK1ROCK2 | |
| SCHEMBL558696 | 0.81 | GSK3B (0.55) | WNT1GSK3BDYRK1AROCK1ROCK2 | |
| SCHEMBL558791 | 0.80 | GSK3B (0.65) | WNT1GSK3BDYRK1AUSP30 | |
| SCHEMBL559024 | 0.77 | DYRK1A (0.65) | WNT1GSK3BDYRK1AROCK2USP30 | |
| SCHEMBL559705 | 0.77 | DYRK1A (0.47) | WNT1GSK3BDYRK1AROCK1ROCK2 | |
| SCHEMBL15583582 | 0.75 | ROCK2 (0.55) | WNT1GSK3BDYRK1AROCK2USP30 | |
| SCHEMBL558997 | 0.74 | DYRK1A (0.51) | WNT1GSK3BDYRK1AROCK2ABL1 | |
| SCHEMBL559683 | 0.74 | WNT1 (0.51) | WNT1GSK3BDYRK1AROCK1ROCK2 | |
| SCHEMBL559265 | 0.74 | GSK3B (0.54) | WNT1GSK3BDYRK1AROCK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | WNT1 1140/4885GSK3B 685/4885DYRK1A 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.